Metformin therapeutic as post-ischemic conditioning agent

Metformin therapeutic as post-ischemic conditioning agent

(HealthDay)—Metformin has therapeutic potential as a post-ischemic conditioning agent, according to a study published online June 23 in Cardiovascular Therapeutics.

Rajesh Ramachandran, Ph.D., and Mini Saraswathy, Ph.D., from the University of Kerala in Thiruvananthapuram, India, examined the role of metformin in preventing apoptotic events preceding ischemic reperfusion injury and its effect on apoptotic markers.

The researchers found that postconditioning with metformin at a concentration of 2.5 µg/mL effectively maintained cell viability and membrane stability of H9C2 cardiomyoblast after ischemic injury. The authors established a decrease in apoptosis cell death via fluorescent staining and Annexin V/FITC flow cytometric analysis. The DNA fragmentation and comet length were significantly reduced in metformin-treated ischemic cells (P = 0.0001). After ischemic injuries, there was an increase in carbonyl content and a decrease in nitrate levels, which were alleviated by treatment with metformin. Metformin treatment also enhanced wound closure. Apoptotic proteins such as FASL and anti-apoptotic proteins such as BcL2, BcL, XL, and p21 were synchronized by metformin.

"The results envisage therapeutic potential of as a post-ischemic conditioning agent," the authors write.


Explore further

Prevalence of metformin use 0.7 percent in prediabetes

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Metformin therapeutic as post-ischemic conditioning agent (2017, June 29) retrieved 18 October 2019 from https://medicalxpress.com/news/2017-06-metformin-therapeutic-post-ischemic-conditioning-agent.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more